Geri
Opthea Ltd (CKDXF) Fiyatı
CKDXF Hisse Senedi Fiyat Grafiği
CKDXF Kazanmak
Opthea Ltd
$0.44
0%
$0
Bugün itibarıyla:Jan 22, 14:05:03 GMT-5
Son Finansal Sonuçlar: Q4 '25
Raporlandı: 2025-08-29
Geçmiş Kazançlar
Dönemlik
Yıllık
EPS
Gelir
Earnings FAQ
CKDXF'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
Opthea Ltd CKDXF'ün son çeyrekteki geliri nasıl performans gösterdi?
Opthea Ltd'in gelir tahmini nedir?
Opthea Ltd'in kazanç kalite puanı nedir?
Opthea Ltd kazançlarını ne zaman rapor eder?
Opthea Ltd'in beklenen kazançları nelerdir?
Opthea Ltd kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$0.44
Açılış fiyatı
$0.29
Günün Aralığı
$0.29 - $0.44
52 haftalık aralık
$0.29 - $0.44
İşlem hacmi
130
Ort.Hacim
0
EPS (TTM)
-0.35
Dividend yield
--
Piyasa Değeri
$601.9M
CKDXF nedir?
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development and research of novel therapeutic products based on targeting Vascular Endothelial Growth Factors. The company is headquartered in Melbourne, Victoria. The company is engaged in developing novel therapies to treat vision-threatening eye diseases, like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D trap inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. The company has initiated two pivotal Phase 3 clinical trials, COAST (Combination OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab), in treatment-naive patients with wet AMD to evaluate the efficacy and safety of sozinibercept in combination with anti-VEGF-A therapies compared to anti-VEGF-A monotherapy. The company is advancing its clinical development program of sozinibercept in DME as well as investigating the feasibility of a co-formulation of sozinibercept with a VEGF-A inhibitor.
Özellikler
Ticaret Stratejileri
Kaynaklar
© 2025 Finture Development Limited. All rights reserved